Bruce C. Trapnell
Pulmonologist-scientist who directs the Rare Lung Diseases Clinical Research Consortium whose MILES trial led to approval of sirolimus for lymphangioleiomyomatosis (LAM); also known for work on pulmonary alveolar proteinosis.
Director, Translational Pulmonary Science Center · Professor, UC Department of Pediatrics · Pulmonologist, Cincinnati Children's
Portrait: Cincinnati Children's Hospital Medical Center
Bruce Trapnell is a lung doctor and researcher at Cincinnati Children's Hospital Medical Center and a professor in the University of Cincinnati Department of Pediatrics. He directs the Translational Pulmonary Science Center. His group showed that GM-CSF autoantibodies cause autoimmune pulmonary alveolar proteinosis and that a hereditary form comes from mutations in the genes CSF2RA and CSF2RB.
He also established and directs the Rare Lung Diseases Clinical Research Consortium. Its study of sirolimus (rapamycin) in lymphangioleiomyomatosis, or LAM, is the 2011 New England Journal of Medicine trial known as MILES. LAM is a rare disease, mostly in women, in which cells with overactive mTOR damage the lungs.
In MILES, sirolimus stabilised lung function over the treatment year, while lung function fell in people on placebo. Trapnell is listed as the last author. The trial led to FDA approval of sirolimus for LAM, one of the clearest examples of an mTOR drug helping patients.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2011 | H | Efficacy and safety of sirolimus in lymphangioleiomyomatosis (MILES) MCC2011 Last author of the MILES trial, in which sirolimus stabilised lung function in lymphangioleiomyomatosis compared with placebo. |
Co-authors in the Atlas 2
People with a profile here who share at least one study with Bruce C. Trapnell.
ShowHide
- Francis X. McCormack Pulmonologist who led the MILES trial, which showed that sirolimus (rapamycin) halts the decline in lung function in lymphangioleiomyomatosis, a rare mTOR-driven lung disease.
- Lisa Young Lung physician-scientist who helped run the first sirolimus trials in lymphangioleiomyomatosis (LAM) and now leads pulmonary medicine at the Children's Hospital of Philadelphia
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.